ReviewCurrent opinion in biotechnology2008
De novo designed synthetic mimics of antimicrobial peptides.
Review in Current opinion in biotechnology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed.
- Combating Antimicrobial Resistance with Hydrophilic and Eco-Friendly Membrane-Active Antibiotics Derived from Biological Nanoparticles.ACS nanoscience Au · 2026Article
- Machine Learning-Guided Design of High-Performance Antifungal Polymers againstACS polymers Au · 2025Article
- Secreted Expression of Thymosin β4 fromBiology · 2025Article
- Development of Xanthoangelol-Derived Compounds with Membrane-Disrupting Effects against Gram-Positive Bacteria.Antibiotics (Basel, Switzerland) · 2024Article
- Antifungal Activity of Brilacidin, a Nonpeptide Host Defense Molecule.Antibiotics (Basel, Switzerland) · 2024Article
- Brilacidin, a host defense peptide mimetic, potentiates ibrexafungerp antifungal activity against the human pathogenic fungusbioRxiv : the preprint server for biology · 2024Article
- Synthesis of new triazole derivatives and their potential applications for removal of heavy metals from aqueous solution and antibacterial activities.Frontiers in chemistry · 2024Article
- Rationally designed PMAP-23 derivatives with enhanced bactericidal and anticancer activity based on the molecular mechanism of peptide-membrane interactions.Amino acids · 2023Article
- A host defense peptide mimetic, brilacidin, potentiates caspofungin antifungal activity against human pathogenic fungi.Nature communications · 2023Article
- Bioengineering Approaches to Fight against Orthopedic Biomaterials Related-Infections.International journal of molecular sciences · 2022Review
- LEGO-Lipophosphonoxins: A Novel Approach in Designing Membrane Targeting Antimicrobials.Journal of medicinal chemistry · 2022Article
- Review
- Antimicrobial Peptide Mimics for Clinical Use: Does Size Matter?Frontiers in immunology · 2022Review
- Multiple roles of ribosomal antimicrobial peptides in tackling global antimicrobial resistance.Royal Society open science · 2022Article
- Spiers Memorial Lecture: Analysis andFaraday discussions · 2021Article
- Allosteric mechanism of signal transduction in the two-component system histidine kinase PhoQ.eLife · 2021Article
- Article
- Revealing the Mechanisms of Synergistic Action of Two Magainin Antimicrobial Peptides.Frontiers in medical technology · 2020Review
- Synthesis and Bioactivity of Polymer-Based Synthetic Mimics of Antimicrobial Peptides (SMAMPs) Made from Asymmetrically Disubstituted Itaconates.Chemistry (Weinheim an der Bergstrasse, Germany) · 2018Article
- Biophysical Investigations Elucidating the Mechanisms of Action of Antimicrobial Peptides and Their Synergism.Biomolecules · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Antimicrobial peptides are small cationic amphiphiles that play an important role in the innate immune system. Given their broad specificity, they appear to be ideal therapeutic agents. As a result, over the last decade, there has been considerable interest in developing them as intravenously administered antibiotics. However, it has proven difficult to accomplish this goal with peptide-based structures. Although it has been possible to solve some relatively simple problems such as susceptibility to proteolysis, more severe problems have included the expense of the materials, toxicity, limited efficacy, and limited tissue distribution. In an effort to overcome these problems, we developed small synthetic oligomers designed to adopt amphiphilic conformations and exhibit potent antimicrobial activity while being nontoxic to host cells. One class of these synthetic mimics of antimicrobial peptides (SMAMPs) is being developed as intravenous antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.